INFECTIOUS COMPLICATIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER TREATED WITH ANTI-PD(L)1 IMMUNE CHECKPOINT INHIBITORS

被引：1
|
作者：
Guo, Matthew [1 ]
Balaji, Aanika [1 ]
Murray, Joseph [1 ]
Reuss, Joshua [2 ]
Steinke, Seema Mehta [3 ]
Naidoo, Jarushka [4 ,5 ]
机构：
[1] Johns Hopkins Sch Med, Baltimore, MD USA
[2] Georgetown Univ, Washington, DC USA
[3] Johns Hopkins Sch Med Univ, Pittsburgh Sch Med, Pittsburgh, PA USA
[4] Johns Hopkins Sch Med, Beaumont Hosp, Baltimore, MD USA
[5] Univ Hlth Sci, Royal Coll Surg Ireland, Dublin, Ireland
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.237
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
237
引用
收藏
页码：A253 / A253
页数：1
相关论文
共 50 条
  • [21] Immune checkpoint inhibitors in advanced non-small cell lung cancer
    Fabre, Elizabeth
    Pecuchet, Nicola
    Cadranel, Jacques
    BULLETIN DU CANCER, 2016, 103 : S138 - S143
  • [22] Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
    Assi, Hazem I.
    Kamphorst, Alice O.
    Moukalled, Nour M.
    Ramalingam, Suresh S.
    CANCER, 2018, 124 (02) : 248 - 261
  • [23] Immune Cell Profiling of Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Antibodies
    Kim, K. H.
    Hur, J. Y.
    Ku, B. M.
    Koh, J.
    Ahn, M.
    Shin, E.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S340 - S340
  • [24] Efficacy of immune checkpoint inhibitors in younger patients with non-small cell lung cancer
    Shinkichi Takamori
    Mototsugu Shimokawa
    Takefumi Komiya
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 13175 - 13184
  • [25] Efficacy of immune checkpoint inhibitors in younger patients with non-small cell lung cancer
    Takamori, Shinkichi
    Shimokawa, Mototsugu
    Komiya, Takefumi
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (14) : 13175 - 13184
  • [26] Determination of Soluble PD-L1 as a Potential Biomarker for Anti-PD(L)1 Therapy in Non-Small Cell Lung Cancer (NSCLC)
    Barba Joaquin, A.
    Zamora Atenza, C.
    Vidal Alcorisa, S.
    Sullivan, I.
    Anguera Palacios, G.
    Ortiz De Juana, M. A.
    Andres Granyo, M.
    Virgili Manrique, A.
    Duenas Cid, N.
    Vethencourt Casado, A.
    Del Carpio Huerta, L.
    Gomila Pons, P.
    Camacho Arellano, S.
    Moron Asensio, S.
    Riudavets Melia, M.
    Molto Valiente, C.
    Callejo Perez, A.
    Majem Tarruella, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2005 - S2006
  • [27] Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors
    Hendriks, Lizza E. L.
    Bootsma, Gerben
    Mourlanette, Jean
    Henon, Clemence
    Mezquita, Laura
    Ferrara, Roberto
    Audigier-Valette, Clarisse
    Mazieres, Julien
    Lefebvre, Corentin
    Duchemann, Boris
    Cousin, Sophie
    le Pechoux, Cecile
    Botticella, Angela
    De Ruysscher, Dirk
    Dingemans, Anne-Marie C.
    Besse, Benjamin
    EUROPEAN JOURNAL OF CANCER, 2019, 116 : 182 - 189
  • [28] The Impact of Inflammatory Serum Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
    Cipriano, E.
    Magalhaes, H.
    Estevinho, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S255 - S255
  • [29] Exosomal PD-L1 expression as non-invasive biomarker for immune checkpoint inhibitors in non-small cell lung cancer
    Gunasekaran, Muthukumar
    Russo, Alessandro
    Cardona, Andres F.
    Perez, Diego de Miguel
    Lapidus, Rena
    Cooper, Brandon
    Kaushal, Sunjay
    Adamo, Vincenzo
    Rolfo, Christian
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [30] Prognostic Nomogram for Advanced Non-Small Cell Lung Cancer Patients Treated With Anti-PD-1 Inhibitors
    Chai, R.
    Fan, Y.
    Zhao, J.
    He, F.
    Han, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S254 - S255
12345